Dr. Vincent L. Yang, M.D.
Nephrology (Kidney) (Nephrology Physician)
1294 S Jones Blvd
Las Vegas, NV 89146
Who else practices at this address →
Clark County includes primary care (9% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 516
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb)
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
NV license 13833 -
Internal Medicine Physician
IL license 125-049168
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mountainview Hospital Las Vegas, NV
Medical groups
- Nephrology and Endocrine Associates Inc (64 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 516
- Services billed
- 3,138
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 831 | 276 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 326 | 161 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 149 | 133 |
| Established patient office or other outpatient visit, 30-39 minutes | 146 | 92 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 135 | 19 |
| Established patient office or other outpatient visit, 20-29 minutes | 31 | 29 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 27 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Calcitriol Other prescribers in Las Vegas, NV | 47 |
| Furosemide Other prescribers in Las Vegas, NV | 38 |
| Amlodipine Besylate Other prescribers in Las Vegas, NV | 38 |
| Hydralazine Hcl Other prescribers in Las Vegas, NV | 31 |
| Carvedilol Other prescribers in Las Vegas, NV | 28 |
| Nifedipine Er (nifedipine) Other prescribers in Las Vegas, NV | 28 |
| Losartan Potassium Other prescribers in Las Vegas, NV | 27 |
| Veltassa (patiromer calcium sorbitex) | 24 |
| Allopurinol Other prescribers in Las Vegas, NV | 21 |
| Clonidine Hcl Other prescribers in Las Vegas, NV | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $279 in total to this clinician.
| Mallinckrodt Hospital Products Inc. | $129 |
|---|---|
| Vantive US Healthcare LLC | $125 |
| Novartis Pharmaceuticals Corporation | $24.42 |
| Food and Beverage | $279 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $131,281 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER)
Vertex Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.